$85.49
0.090.11%
At Close: -
$85.49
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Merit Medical Systems
MMSINASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Merit Medical Systems (NASDAQ:MMSI) Stock, Analyst Ratings, Price Targets, Forecasts
Merit Medical Systems Inc has a consensus price target of $90.58 based on the ratings of 12 analysts. The high is $125 issued by Canaccord Genuity on July 2, 2024. The low is $70 issued by Canaccord Genuity on August 28, 2023. The 3 most-recent analyst ratings were released by Barrington Research, Barrington Research, and Canaccord Genuity on July 16, 2024, July 2, 2024, and July 2, 2024, respectively. With an average price target of $108.33 between Barrington Research, Barrington Research, and Canaccord Genuity, there's an implied 26.72% upside for Merit Medical Systems Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barrington Research
Canaccord Genuity
Needham
Baird
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Merit Medical Systems
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 16.97% | Barrington Research | Michael Petusky | $100 → $100 | Maintains | Outperform | Get Alert |
| 07/02/2024 | Buy Now | 16.97% | Barrington Research | Michael Petusky | $100 → $100 | Maintains | Outperform | Get Alert |
| 07/02/2024 | Buy Now | 46.22% | Canaccord Genuity | Jon Young | $102 → $125 | Maintains | Buy | Get Alert |
| 07/01/2024 | Buy Now | 8.78% | Needham | Mike Matson | $85 → $93 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 12.29% | Baird | David Rescott | → $96 | Initiates | → Outperform | Get Alert |
| 05/01/2024 | Buy Now | 19.31% | Canaccord Genuity | Jon Young | $112 → $102 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 16.97% | Barrington Research | Michael Petusky | $98 → $100 | Maintains | Outperform | Get Alert |
| 05/01/2024 | Buy Now | 13.46% | Piper Sandler | Jason Bednar | $95 → $97 | Maintains | Overweight | Get Alert |
| 05/01/2024 | Buy Now | -0.57% | Needham | Mike Matson | $88 → $85 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 14.63% | Barrington Research | Michael Petusky | $98 → $98 | Maintains | Outperform | Get Alert |
| 04/11/2024 | Buy Now | 2.94% | Needham | Mike Matson | → $88 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 2.94% | CL King | Kristen Stewart | → $88 | Initiates | → Buy | Get Alert |
| 02/29/2024 | Buy Now | 1.77% | Oppenheimer | Steven Lichtman | $82 → $87 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 14.63% | Barrington Research | Michael Petusky | $96 → $98 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 2.94% | Needham | Mike Matson | $81 → $88 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 31.01% | Canaccord Genuity | Jon Young | $102 → $112 | Maintains | Buy | Get Alert |
| 02/07/2024 | Buy Now | 1.77% | B of A Securities | Craig Bijou | → $87 | Initiates | → Neutral | Get Alert |
| 01/30/2024 | Buy Now | 4.11% | Raymond James | Jayson Bedford | $84 → $89 | Maintains | Outperform | Get Alert |
| 01/12/2024 | Buy Now | 11.12% | Piper Sandler | Jason Bednar | $88 → $95 | Maintains | Overweight | Get Alert |
| 12/21/2023 | Buy Now | 16.97% | Canaccord Genuity | Jon Young | $76 → $100 | Upgrade | Hold → Buy | Get Alert |
| 10/27/2023 | Buy Now | 12.29% | Barrington Research | Michael Petusky | $95 → $96 | Maintains | Outperform | Get Alert |
| 10/27/2023 | Buy Now | -5.25% | Needham | Mike Matson | $96 → $81 | Maintains | Buy | Get Alert |
| 09/27/2023 | Buy Now | 12.29% | Needham | Mike Matson | → $96 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | -18.12% | Canaccord Genuity | William Plovanic | $86 → $70 | Maintains | Hold | Get Alert |
| 08/16/2023 | Buy Now | 11.12% | Barrington Research | Michael Petusky | → $95 | Reiterates | Outperform → Outperform | Get Alert |
| 07/26/2023 | Buy Now | 12.29% | Needham | Mike Matson | → $96 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 7.61% | Piper Sandler | Jason Bednar | $85 → $92 | Maintains | Overweight | Get Alert |
| 07/06/2023 | Buy Now | 11.12% | Barrington Research | Michael Petusky | → $95 | Reiterates | Outperform → Outperform | Get Alert |
| 06/09/2023 | Buy Now | 11.12% | Barrington Research | Michael Petusky | $90 → $95 | Maintains | Outperform | Get Alert |
| 06/09/2023 | Buy Now | 12.29% | Needham | Mike Matson | $90 → $96 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 8.78% | Raymond James | Jayson Bedford | $88 → $93 | Maintains | Outperform | Get Alert |
| 04/27/2023 | Buy Now | -0.57% | Piper Sandler | Jason Bednar | $77 → $85 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | 5.28% | Barrington Research | Michael Petusky | $78 → $90 | Maintains | Outperform | Get Alert |
| 04/27/2023 | Buy Now | -5.25% | Wells Fargo | Larry Biegelsen | $74 → $81 | Maintains | Equal-Weight | Get Alert |
| 04/27/2023 | Buy Now | 2.94% | Raymond James | Jayson Bedford | $86 → $88 | Maintains | Outperform | Get Alert |
| 04/27/2023 | Buy Now | 5.28% | Needham | Mike Matson | $84 → $90 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | -1.74% | Needham | Mike Matson | $78 → $84 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 0.6% | Raymond James | Jayson Bedford | $80 → $86 | Maintains | Outperform | Get Alert |
| 04/12/2023 | Buy Now | -8.76% | Barrington Research | Michael Petusky | → $78 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | -8.76% | Barrington Research | Michael Petusky | → $78 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | -9.93% | Piper Sandler | Jason Bednar | $73 → $77 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -6.42% | Raymond James | Jayson Bedford | $72 → $80 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | -8.76% | Needham | Mike Matson | $73 → $78 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -15.78% | Canaccord Genuity | William Plovanic | → $72 | Downgrade | Buy → Hold | Get Alert |
| 10/27/2022 | Buy Now | -15.78% | Raymond James | Jayson Bedford | $71 → $72 | Maintains | Outperform | Get Alert |
| 10/14/2022 | Buy Now | -26.31% | Canaccord Genuity | William Plovanic | $69 → $63 | Maintains | Buy | Get Alert |
| 09/02/2022 | Buy Now | -19.29% | Canaccord Genuity | William Plovanic | $67 → $69 | Maintains | Buy | Get Alert |
| 07/28/2022 | Buy Now | -16.95% | Raymond James | Jayson Bedford | $72 → $71 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | -15.78% | Raymond James | Jayson Bedford | $73 → $72 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | -14.61% | Needham | Mike Matson | $83 → $73 | Maintains | Buy | Get Alert |
| 10/29/2021 | Buy Now | -13.44% | Wells Fargo | Lawrence Biegelsen | — | Maintains | Equal-Weight | Get Alert |
| 07/30/2021 | Buy Now | -14.61% | Raymond James | Jayson Bedford | — | Maintains | Outperform | Get Alert |
| 07/30/2021 | Buy Now | -20.46% | Wells Fargo | Lawrence Biegelsen | — | Maintains | Equal-Weight | Get Alert |
| 07/30/2021 | Buy Now | -2.91% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Merit Medical Systems (MMSI) stock?
The latest price target for Merit Medical Systems (NASDAQ:MMSI) was reported by Barrington Research on July 16, 2024. The analyst firm set a price target for $100.00 expecting MMSI to rise to within 12 months (a possible 16.97% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Merit Medical Systems (MMSI)?
The latest analyst rating for Merit Medical Systems (NASDAQ:MMSI) was provided by Barrington Research, and Merit Medical Systems maintained their outperform rating.
When was the last upgrade for Merit Medical Systems (MMSI)?
The last upgrade for Merit Medical Systems Inc happened on December 21, 2023 when Canaccord Genuity raised their price target to $100. Canaccord Genuity previously had a hold for Merit Medical Systems Inc.
When was the last downgrade for Merit Medical Systems (MMSI)?
The last downgrade for Merit Medical Systems Inc happened on December 20, 2022 when Canaccord Genuity changed their price target from N/A to $72 for Merit Medical Systems Inc.
When is the next analyst rating going to be posted or updated for Merit Medical Systems (MMSI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merit Medical Systems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merit Medical Systems was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Merit Medical Systems (MMSI) correct?
While ratings are subjective and will change, the latest Merit Medical Systems (MMSI) rating was a maintained with a price target of $100.00 to $100.00. The current price Merit Medical Systems (MMSI) is trading at is $85.49, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.